Prevention & lipids

ANGPTL4 Inhibition in Adults with Elevated Triglyceride Levels

N Engl J MedPublished two-part, phase 2b, double-blind, randomized, placebo-controlled trial

Authors' conclusion

Inhibition of ANGPTL4 with MAR001 significantly reduced fasting triglyceride levels at 12 weeks. (Funded by Marea Therapeutics; TYDAL-TIMI 78 ClinicalTrials.gov number, NCT07028749.).

Study context

Population
Adults with a nonfasting triglyceride level of at least 175 mg per deciliter and remnant cholesterol of at least 35 mg per deciliter at initial screening, then fasting triglyceride of at least 150 mg per deciliter and remnant cholesterol of at least 30 mg per deciliter on confirmatory screeningenrolled, 235 received at least one dose and were included in the primary efficacy analyses · 177 (MAR001) · 59 (placebo)
Participants
236 adults
Comparison
MAR001 at a dose of 300, 450, or 900 mg vs matching placebo
  • Placebon = 59
Primary endpoint
Percent change from baseline in the fasting triglyceride level (placebo-adjusted change)
Follow-up
Week 12
Methodological detailspart A reported
  • Part A reported

Primary result

As reported in the abstract

Percent change from baseline in the fasting triglyceride level (placebo-adjusted change)

Placebo-adjusted least-squares mean percent change

−39.1 percentage points

P < 0.001

MAR001 300 mg vs placebo

Placebo-adjusted least-squares mean percent change

−40.5 percentage points

P < 0.001

MAR001 450 mg vs placebo

Placebo-adjusted least-squares mean percent change

−45.3 percentage points

P < 0.001

MAR001 900 mg vs placebo

Further findings

Baseline characteristics

Mean age
60.4 years
Women
39%
Median triglyceride level
249.5 mg per deciliter (interquartile range, 210.0 to 313.0)

Safety

Adverse events — placebo
78%
  • Adverse events: pooled MAR001 69%

Original publication

ANGPTL4 Inhibition in Adults with Elevated Triglyceride Levels. N Engl J Med. Published 9 November 2026. doi:10.1056/nejmoa2612463

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.